ABOUT

INOLYSIS is a new company founded by Professor George Kollias in 2025 focusing on the development of novel drugs that target fibroblasts to mitigate chronic inflammation, fibrosis and cancer. The company builds on previous research in the Kollias lab that has identified several compounds that effectively disrupt pathogenic fibroblast activation. By targeting fibroblasts - an underexplored yet central driver of disease pathogenesis-, INOLYSIS is pioneering a new approach to treat chronic inflammatory and fibrotic diseases. Our innovative small molecules address the root causes of fibrotic and inflammatory conditions, offering new hope where current treatments fall short.

​

Backed by cutting-edge science and a deep understanding of fibroblast biology, we are employing a multidisciplinary pipeline to develop novel therapeutics designed to halt disease progression and restore tissue health. With a strong foundation in translational research and a commitment to clinical impact, we aim to redefine the standard of care in fibrosis and related diseases.